Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Journal of Italian Cinema and Media Studies ; 10(2):181-185, 2022.
Article in English | Web of Science | ID: covidwho-1666786


In this interview, which was conducted during the COVID-19 pandemic in early March 2021, Lorenzo Codelli reflects on Latin American cinema and its underlying aesthetics, as well as on the global influence of Italian cinema, in particular neorealism, on filmmakers such as Ruy Guerra, Fernando Solanas and Alfonso Cuaron, among others. In recent years, the Latin American film industry has produced commercially successful films, such as Cuaron's Roma (2018), but few movies receive international distribution in particular if directed a Name) (2019), which premiered at Cannes' Directors' Fornight and has won many awards, is a case in point. Of special interest is Codelli's point of view on the status of contemporary national cinemas and the impact of popular television series on its very survival.

Journal of Italian Cinema and Media Studies ; 9(3):445-460, 2021.
Article in English | Scopus | ID: covidwho-1295528


In the following interview, which was conducted during the COVID-19 shut-down in December 2020, Liliana Cavani reflects on her cinema and its underlying aesthetics, on current issues such as diversity and gender equality. She reminisces on her formative years and the impact of her anti-fascist grandparents as well as of those open-minded RAI executives who hired her as a freelance professional. She discusses her historical documentaries, her approach to the revolutionary experience of Francis and Clare of Assisi, and her stage production of Eduardo De Filippo’s Filumena Marturano (2016). Of special interest are the director’s comments on the new release of a re-mastered DVD of The Night Porter in England and some critics’ attempts to re-categorize her as a filmmaker obsessed with the corporeality of Eros. She also introduces her new screenplay, written in collaboration with physicist Carlo Rovelli.1. © 2021 Intellect Ltd Interview. English language.

Pharmaceuticals ; 14(4):06, 2021.
Article in English | MEDLINE | ID: covidwho-1210243


The Coronavirus Disease-19 (COVID-19) pandemic has caused more than 100,000,000 cases of coronavirus infection in the world in just a year, of which there were 2 million deaths. Its clinical picture is characterized by pulmonary involvement that culminates, in the most severe cases, in acute respiratory distress syndrome (ARDS). However, COVID-19 affects other organs and systems, including cardiovascular, urinary, gastrointestinal, and nervous systems. Currently, unique-drug therapy is not supported by international guidelines. In this context, it is important to resort to adjuvant therapies in combination with traditional pharmacological treatments. Among natural bioactive compounds, palmitoylethanolamide (PEA) seems to have potentially beneficial effects. In fact, the Food and Drug Administration (FDA) authorized an ongoing clinical trial with ultramicronized (um)-PEA as an add-on therapy in the treatment of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection. In support of this hypothesis, in vitro and in vivo studies have highlighted the immunomodulatory, anti-inflammatory, neuroprotective and pain-relieving effects of PEA, especially in its um form. The purpose of this review is to highlight the potential use of um-PEA as an adjuvant treatment in SARS-CoV-2 infection.